自调控基因治疗改善Rett综合征小鼠模型表型并克服基因剂量敏感性
研究开发了基于microRNA前馈环路的EXACT基因调控系统,使转基因表达更一致并防止过表达。在RTT小鼠模型中,AAV9载体NGN-401经脑室内注射可延长雄性半合子小鼠生存并改善RTT样表型,且在雌性小鼠和幼年非人灵长类中耐受良好,支持启动NGN-401首次儿科人体试验。
要点
- EXACT系统通过microRNA前馈环路实现更一致的转基因表达并防止过表达。
- NGN-401经脑室内注射延长雄性Mecp2-/y小鼠生存并改善RTT样表型。
- NGN-401在雌性Mecp2+/-小鼠和健康幼年非人灵长类中耐受良好。
核心结论
- EXACT自调控MECP2基因治疗载体NGN-401可改善RTT小鼠模型表型并克服基因剂量敏感性,支持启动首次儿科人体试验。
研究设计与样本
- 研究采用细胞筛选试验、体外实验及野生型小鼠、RTT模型小鼠和健康幼年非人灵长类的体内测试。
- 在细胞和体内测试基础上确定了AAV9自调控MECP2基因治疗载体的最优构型,命名为NGN-401。
- NGN-401通过脑室内注射递送至新生雄性Mecp2-/y半合子小鼠。
主要发现
- 与常规构建体相比,EXACT-MECP2构建体表现出更窄的细胞蛋白丰度范围。
- EXACT环路调控程度在体外及野生型小鼠和RTT模型小鼠中随转基因剂量升高而增加。
- NGN-401递送至新生雄性Mecp2-/y半合子小鼠后,与载体处理动物相比延长了生存并改善了RTT样表型。
- NGN-401在雌性Mecp2+/-小鼠和健康幼年非人灵长类中耐受良好,而常规构建体则引起毒性。
关键数值与推荐
- EXACT-MECP2构建体与常规构建体相比,细胞蛋白丰度范围更窄。
- NGN-401在雄性Mecp2-/y半合子小鼠中延长生存并改善RTT样表型,与载体处理组相比。
- NGN-401在雌性Mecp2+/-小鼠和健康幼年非人灵长类中耐受良好,常规构建体引起毒性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Conventional methods of gene transfer lead to inconsistent transgene expression within cells. This variability can be problematic, particularly in conditions like Rett syndrome (RTT), a neurological disorder caused by mutations in the MECP2 (methyl-CpG binding protein 2) gene, because overexpression of MECP2 can also cause adverse effects. To address these challenges, we devised a gene regulation system called Expression Attenuation via Construct Tuning (EXACT), which uses a self-contained, microRNA-based feed-forward loop that not only ensures more consistent transgene expression but also protects against excessive expression. Through cell-based screening assays, we demonstrated the ability of the EXACT circuit to modulate the expression of full-length human MeCP2. Compared with a conventional construct, an EXACT-MECP2 construct exhibited a narrower range of cellular protein abundance. Furthermore, the degree of regulation by the EXACT circuit increased with higher transgene doses in vitro and in wild-type mice and mice modeling RTT. On the basis of cellular and in vivo testing, we identified an optimal configuration for the adeno-associated virus serotype 9 (AAV9) construct for self-regulated MECP2 gene therapy, designated NGN-401. Delivery of NGN-401 to neonatal male Mecp2-/y hemizygous mice via intracerebroventricular injection resulted in prolonged survival and amelioration of RTT-like phenotypes compared with vehicle-treated animals. NGN-401 was also well tolerated by female Mecp2+/- mice and healthy juvenile nonhuman primates, in contrast with a conventional construct, which caused toxicity. The results from these studies underpin a first-in-human pediatric trial of NGN-401 in RTT (ClinicalTrials.gov, NCT05898620).
引用
- Ross PD, Gadalla KKE, Thomson SR, et al. Self-regulating gene therapy ameliorates phenotypes and overcomes gene dosage sensitivity in a mouse model of Rett syndrome. Sci Transl Med. 2025. PMID: 40173263. doi:10.1126/scitranslmed.adq3614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。